

25th EDRN Steering Committee Meeting
October 2 - 4, 2012
Westin Riverwalk Hotel
San Antonio, Texas

**Agenda**

**Tuesday, October 2, 2012**

7:00 – 8:00 a.m.  Sign-In and Continental Breakfast
*Navarro B Foyer*

8:00 – 8:15 a.m.  Welcome and Opening of Steering Committee Meeting
*Navarro B*
Ian Thompson, M.D., The University of Texas Health Sciences Center at San Antonio

8:15 – 8:40 a.m.  State of the EDRN
*Navarro B*
Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

8:40 – 10:35 a.m.  EDRN Collaborative Projects
*Navarro B*
Chair: Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

8:40 – 9:15 a.m.  EDRN Canary Never Smokers Lung Cancer Project
  ○ Adi Gazdar, M.D., University of Texas Southwestern Medical Center
  ○ Sam Hanash, M.D., Ph.D., The University of Texas MD Anderson Cancer Center

9:15 – 9:30 a.m.  Discussion

9:30 – 9:50 a.m.  Break

9:50 – 10:20 a.m.  EDRN Canary Prostate Active Surveillance Study (PASS)
  ○ James Brooks, M.D., Stanford University Medical Center
  ○ Ziding Feng, Ph.D., Fred Hutchinson Cancer Research Center

10:20 – 10:35 a.m.  Discussion
25th EDRN Steering Committee Meeting
October 2 - 4, 2012
Westin Riverwalk Hotel
San Antonio, Texas

Tuesday, October 2, 2012 Continued

10:35 a.m. – 12:00 p.m. Research Projects on Overdiagnosis and Mutational Hotspots Sequencing

Navarro B

10:35 – 10:45 a.m. NCI Expectations
   ○ Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute
   ○ Nadarajen A. Vydelingum, Ph.D., FRSPH, National Cancer Institute

10:45 a.m. – 12:00 p.m. Overview of Overdiagnosis and Mutational Hotspots Sequencing Projects
EDRN Investigators with projects supported by these supplements (5-min presentations and no more than 5 slides)

Research Projects on Overdiagnosis
   ○ William Grady, M.D., Fred Hutchinson Cancer Research Center
   ○ Tony Hollingsworth, Ph.D., University of Nebraska
   ○ Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center
   ○ Dan Mercola, M.D., Ph.D., University of California, Irvine
   ○ William Rom, M.D., M.P.H., New York University
   ○ Ian Thompson, M.D., The University of Texas Health Sciences Center at San Antonio
   ○ Hui Zhang, Ph.D., Johns Hopkins School of Medicine

Research Projects on Mutational Hotspots Sequencing
   ○ Steven Dubinett, M.D., University of California, Los Angeles
   ○ Ann Killary, Ph.D., The University of Texas MD Anderson Cancer Center
   ○ Sanford Markowitz, M.D., Case Western Reserve University
   ○ David Sidransky, M.D., Johns Hopkins School of Medicine
# 25th EDRN Steering Committee Meeting
**October 2 - 4, 2012**
**Westin Riverwalk Hotel**
**San Antonio, Texas**

**Tuesday, October 2, 2012 Continued**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 – 1:00 p.m.</td>
<td>Lunch (On Your Own)</td>
</tr>
<tr>
<td>1:00 – 5:00 p.m.</td>
<td><strong>Collaborative Group Meetings</strong></td>
</tr>
<tr>
<td>Camino Room</td>
<td>Breast and Gynecological Cancers</td>
</tr>
<tr>
<td>Olivares Room</td>
<td>Gastrointestinal Cancers</td>
</tr>
<tr>
<td>Zapata Room</td>
<td>Lung and Upper Aerodigestive Cancers</td>
</tr>
<tr>
<td>Navarro B</td>
<td>Prostate and Urological Cancers</td>
</tr>
<tr>
<td>5:00 – 6:00 p.m.</td>
<td><strong>Closed Session EDRN PIs and NCI Staff only</strong></td>
</tr>
<tr>
<td>Navarro B</td>
<td>Election of Chairs and Co-chairs for EDRN and the EDRN Collaborative Groups</td>
</tr>
<tr>
<td>6:00 – 7:00 p.m.</td>
<td><strong>BRL Interest Group Meeting</strong></td>
</tr>
<tr>
<td>Navarro B</td>
<td></td>
</tr>
<tr>
<td>6:00 – 7:00 p.m.</td>
<td><strong>Informatics Working Group</strong></td>
</tr>
<tr>
<td>Zapata Room</td>
<td></td>
</tr>
</tbody>
</table>

**Wednesday, October 3, 2012**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 – 8:00 a.m.</td>
<td>Sign-In and Continental Breakfast</td>
</tr>
<tr>
<td>Navarro B</td>
<td></td>
</tr>
<tr>
<td>8:00 – 10:00 a.m.</td>
<td><strong>Dialogue with Other Government Programs</strong></td>
</tr>
<tr>
<td>Navarro B</td>
<td></td>
</tr>
<tr>
<td>8:00 – 8:20 a.m.</td>
<td>Bioinformatics Collaborations with the EDRN</td>
</tr>
<tr>
<td></td>
<td>Dan Crichton, M.S., NASA Jet Propulsion Laboratory</td>
</tr>
<tr>
<td>8:20 – 8:40 a.m.</td>
<td>Clinical Proteomics Research</td>
</tr>
<tr>
<td></td>
<td>Henry Rodriguez, Ph.D., M.B.A., National Cancer Institute</td>
</tr>
<tr>
<td>8:40 – 9:00 a.m.</td>
<td>Integrative Cancer Biology Program</td>
</tr>
<tr>
<td></td>
<td>Dan Gallahan, Ph.D., National Cancer Institute</td>
</tr>
</tbody>
</table>
25th EDRN Steering Committee Meeting
October 2 - 4, 2012
Westin Riverwalk Hotel
San Antonio, Texas

Wednesday, October 3, 2012 Continued

Dialogue with Other Government Programs Continued

9:00 – 9:20 a.m. Pacific Northwest National Laboratory and the Navarro B
National Cancer Institute Collaborative Studies
Karin Rodland, Ph.D., Pacific Northwest National Laboratory

9:20 – 9:40 a.m. Barrett’s Esophagus Translational Research
Network (BETRNet)
Ellen Richmond, R.N., M.S., G.N.P.

9:40 – 10:00 a.m. Overview and ERG Focused Evaluations of
Prostate Cancer
Shiv Srivastava, Ph.D., Center for Prostate Disease Research (CPDR), Uniformed Services
University of the Health Sciences

10:00 – 10:20 a.m. Break

10:20 – 12:00 p.m. Industry Forum
Navarro B

Chair: Craig Tuttle, M.S., M.B.A., President and CEO, Transgenomic, Inc.
NCI Program Liaison: Lynn Sorbara, Ph.D., National Cancer Institute

10:20 – 10:40 a.m. Introduction and Update on EDRN-Industry
Collaborations
Craig Tuttle, M.S., M.B.A., President and CEO, Transgenomic, Inc.

10:40 – 10:45 a.m. Q/A

10:45 - 11:05 a.m. Advances in the Diagnosis and Management of
Bladder Cancer
Angelo De Marzo, M.D., Ph.D., CMO for Predictive Biosciences, Inc. and Associate Professor of Pathology, Oncology, Urology, Johns Hopkins University

11:05 -11:10 a.m. Q/A
Wednesday, October 3, 2012 Continued

Industry Forum Continued

11:35 – 11:55 a.m.  International Prospective Study for Hepatocellular Carcinoma Surveillance Using Biomarkers
Navarro B
Hiro Yamada, M.S., Manager of Clinical Affairs, Wako Life Sciences, Inc.

11:55 – 12:00 p.m.  Q/A

12:00 – 1:30 p.m.  Lunch (On Your Own)

12:00 – 1:30 p.m.  EDRN EC Meeting (Closed Session)
Olivares Room

1:30 – 5:00 p.m.  Defining Molecularly-informed Natural History of Occult Neoplasms
Navarro B

1:30 – 1:45 p.m.  Objective and Implementation Plan
Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

1:45 – 2:00 p.m.  Case Study
Ian Thompson, M.D., The University of Texas Health Sciences Center at San Antonio

2:00 – 5:00 p.m.  Breakout Sessions

There will be three groups and each will discuss questions related to Defining Molecularly-informed Natural History of Occult Neoplasms. EDRN PIs will be assigned to a specific group so there are PIs from each collaborative group in each discussion group. The goal is to develop specific, concrete recommendations on the development of a research program to address the problems of over and under diagnosis. (Discussion Leaders and room assignments on next page)
Wednesday, October 3, 2012 Continued

Breakout Session Continued

Discussion Leader Group 1:
Navarro B  
Brian Reid, M.D., Ph.D., Fred Hutchinson Cancer Research Center

Discussion Leader Group 2:
Villa Room  
Joshua LaBaer, M.D., Ph.D., Arizona State University

Discussion Leader Group 3:
Zapata Room  
Mark Rubin, M.D., Weill Cornell Medical College

5:00 – 6:00 p.m.
Zapata Room  
Common Data Elements Working Group Meeting

5:00 – 7:00 p.m.
Navarro B  
Proteomics Interest Group Meeting

Thursday October 4, 2012

7:00 – 8:00 a.m.
Navarro B Foyer  
Sign-In and Continental Breakfast

8:00 – 8:10 a.m.
Navarro B  
Announcement of new Co-chair of EDRN Steering Committee and new Chair and Co-Chairs of Collaborative Groups

8:10 – 8:30 a.m.
Navarro B  
Administrative Updates
  ○ Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute
  ○ Sean Hine, Office of Grant Administration, National Cancer Institute

8:30 – 9:30 a.m.
Navarro B  
Ongoing and Potential Biomarker Validation Trials

8:30 – 8:50 a.m.
Colorectal Cancer Biomarker Validation Trial  
Dean Brenner, M.D., University of Michigan
25th EDRN Steering Committee Meeting
October 2 - 4, 2012
Westin Riverwalk Hotel
San Antonio, Texas

Thursday, October 4, 2012 Continued

Ongoing and Potential Biomarker Validation Trials Continued

8:50 – 9:10 a.m.
Navarro B
Validation of T2-ERG for Prostate Cancer
Martin Sanda, M.D., Beth Israel Deaconess Medical Center/Harvard Medical School

9:10 – 9:30 a.m.
Discovery and Preliminary Validation of Novel Early Detection Biomarkers for Triple-Negative Breast Cancer Using Preclinical Plasma Samples from the Women’s Health Initiative Observational Study
Christopher Li, M.D., Ph.D., Fred Hutchinson Cancer Research Center

9:30 – 10:15 a.m.
Team Projects Updates (15 minutes each)
Navarro B
• Prostate
• Breast
• Ovarian

10:15 – 10:35 a.m.
Break

10:35 – 11:20 a.m.
Team Projects Updates Continued
• Lung
• Pancreas
• Colon

11:20 a.m. – 12:20 p.m.
Reports from Natural History Discussion Groups
Navarro B

12:20 – 12:30 p.m.
Final Remarks
Navarro B
• Ian Thompson, M.D., The University of Texas Health Sciences Center at San Antonio
• Sudhir Srivastava, Ph.D., M.P.H., National Cancer Institute

12:30 p.m.
Adjourn